priors.science/reviews/p2y12-antiplatelets

P2Y12 Antiplatelets

The current evidence on 17 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

17claims tracked

77primary papers reviewed

9 Aug 2026latest evidence review

Weeklyre-scored against new papers

6 Established · 6 Likely · 3 Uncertain · 2 Doubtful | four-reviewer panel · PICO Framework

ClaimStandingEvidence certaintyCorpus

Prasugrel harm in prior stroke patientsPrasEstablished96%—

Prasugrel reduces MACE vs clopidogrel in ACS patients undergoing PCIPrasEstablished93%16

Prasugrel major bleeding vs clopidogrelPrasEstablished93%—

Ticagrelor increases major bleeding vs clopidogrel in ACS patientsTcaEstablished93%16

Clopidogrel-aspirin reduces stroke recurrence vs aspirin after TIAStrokeEstablished90%1

P2Y12 monotherapy after short DAPT reduces bleeding in ACS patientsDeescalationEstablished87%5

CYP2C19 loss-of-function alleles increase MACE risk with clopidogrel after PCIGenotypeLikely80%—

Abbreviated DAPT reduces bleeding in high bleeding risk PCI patientsDurationLikely80%6

Ticagrelor reduces MACE and mortality vs clopidogrel in ACSTcaLong-standingLikely80%19

Cangrelor reduces stent thrombosis vs clopidogrel loading during PCICangrelorLikely76%—

Short DAPT is noninferior to 12-month DAPT for ischemic events post-PCIDurationLikely73%—

Genotype-guided P2Y12 selectionGenotypeLikely72%1

Extended DAPT reduces MI but increases non-cardiac mortality vs 12-month DAPTDurationUncertain67%—

DAPT benefit in TIA and minor stroke is confined to the first 21 daysStrokeUncertain65%—

Clopidogrel is noninferior to ticagrelor in elderly ACS patientsTcaLong-standingUncertain55%12

De-escalation to clopidogrel reduces bleeding vs potent P2Y12 continuation after ACSDeescalationDoubtful42%—

Cangrelor improves outcomes vs oral P2Y12 in cardiogenic shock PCICangrelorDoubtful34%1

Track P2Y12 Antiplatelets.

These claims are re-scored against new papers every week. Track this topic for the full review, including each claim’s challenge and the papers behind it.

Track this topic →

Standing — what the evidence certainty means

Established≥ 85%Strong, consistent evidence. Unlikely to change.

Likely70–84%Well supported, with some gaps or indirect evidence.

Uncertain50–69%Mixed or limited evidence. Genuinely open.

Doubtful30–49%Little support; the weight of evidence leans against it.

Refuted< 30%The evidence contradicts it — confidently false as stated.

Where the evidence sits in time

Long-standingMost of this evidence is older than the rest of this field.